CClinicalTrials.gg
RecruitingNCT06506344Updated Jun 4, 2026

Syncing Screening and Services for Suicide Prevention Across Health and Jail Systems

An interventional study of 5S Trial in Suicide Prevention, sponsored by Henry Ford Health System. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Henry Ford Health System · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
5,250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to harmonize jail release record data with electronic health record data in order to connect patients to an evidence-based suicide prevention and clinical care pathway upon jail release.

Read the detailed description

This study is designed to test the effectiveness of a care pathway delivered at the time of jail release, to increase behavioral health services engagement and prevent suicide attempt. There are 3 primary aims of this study: (1) Examine the effectiveness of the intervention on suicide attempt outcomes. (2) Evaluate the impact of the intervention on behavioral health utilization mechanisms. (3) Evaluate implementation outcomes and processes to guide future implementation and research, including: cost and cost-effectiveness; scalability; sustainability; feasibility, acceptability, and appropriateness to providers/systems; and implementation strategies.

02

Conditions studied

  • Suicide Prevention

Browse trials for

03

In context

Suicide Prevention

190 studies on the registry are indexed under Suicide Prevention; 87 are open to participants now.

This study's planned enrollment of 5,250 is above the median of 150 across 169 interventional studies indexed under Suicide Prevention.

Browse Suicide Prevention studies →

Lead sponsor

Henry Ford Health System is the lead sponsor of 293 studies on the registry; 50 are open to participants now.

Of its 35 completed or terminated interventional studies of FDA-regulated products, 23 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 18 years of age or older
  • Released from jail between February 2021 and July of 2028
  • Had a prior primary care visit or behavioral health visit at a participating health system in the past 3 years

Exclusion criteria

Exclusion Criteria:

  • Does not currently reside in the same state as the study site (i.e.- Michigan, Minnesota)
  • Would require a translator to participate in the research according to EHR data
  • Previously requested to be excluded from research
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
5,250 participants (estimated)

Study arms

  • Experimental
    5S Trial

    Participants will receive an intervention aimed at suicide prevention in this group.

    Behavioral: 5S Trial

  • No intervention
    No-Contact Control Group

    Participants will be able to engage with healthcare services as usual and will have no knowledge of their involvement in the study.

Interventions

  • Behavioral5S Trial

    Participants will receive caring contacts/recruitment outreach, suicide risk screening, suicide safety planning, and, if indicated, connection to healthcare services, resources and the CLASP virtual outreach intervention.

06

What researchers measure

Primary outcomes

  1. Composite measures of suicide attempt and death

    Nonfatal medically treated suicide attempts will be identified using diagnosis and encounter codes from all inpatient, outpatient, and emergency department encounters recorded in the EHR (for services delivered by participating systems) or claims (for outside services). All suicide deaths will be identified via linkage to regularly updated state mortality data and the National Death Index (NDI). Suicide deaths will be identified using ICD-10 codes indicating definite or possible self-inflicted injury, or deaths identified as suicides in official state government mortality data (updated monthly in each site).

    Time frame: 6-months from jail release date

07

Study locations

2 of 2 sites recruiting
  • Henry Ford Health
    Detroit, Michigan 48202, United States
    Recruiting
  • HealthPartners Institute
    Bloomington, Minnesota 55425, United States
    Recruiting
08

References and documents

Publications

  • Wisnieski DM, Rossom RC, Weinstock LM, Johnson J, Miley K, Gaudiano BA, Benz MB, Borgert-Spaniol C, Graves HR, Norwood R, Kazan R, Starkey C, Kim H, Fletcher L, Kane S, Hu Y, Farrell Z, Strong S, Yeh HH, Miller T, Jones R, Morey K, Ahmedani BK. Study protocol for a type I hybrid effectiveness trial of strategies to prevent suicide attempts among adults recently released from jail. Contemp Clin Trials. 2026 Feb;161:108184. doi: 10.1016/j.cct.2025.108184. Epub 2025 Dec 15. PubMed 41407099 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06506344
Lead sponsor
Henry Ford Health System
Collaborators
National Institute of Mental Health (NIMH), Michigan State University, HealthPartners Institute, Brown University
Responsible party
Brian Ahmedani (Principal Investigator, Henry Ford Health System) — Principal investigator
First posted
Jul 17, 2024
Start date
Jun 24, 2024
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jun 4, 2026

Study contacts

Diane Wisnieski, MSW
Contact
dwisnie2@hfhs.org
313-319-6084
Brian Ahmedani, PhD, MSW
principal investigator · Henry Ford Health
Lauren Weinstock, PhD
principal investigator · Brown University
Rebecca Rossom, MD, MS
principal investigator · HealthPartners Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion